MSc, Digital Pathology Analyst, Molecular Histology Facility University of Birmingham
A University of Birmingham (UoB) graduate in Biochemistry, Kelly trained as a Biomedical Scientist in the private healthcare sector and went on to practice in NHS laboratories. Following an MSc Genomic Medicine at UoB, Kelly joined the emerging digital pathology service at the Advanced Therapies Facility at UoB. Here Kelly has been progressing staining, imaging and analytical methods on various platforms including the Leica Bond RX, Akoya Vectra Polaris 2, Nanostring GeoMx and Visiopharm, and bolstered by a recent WT MUE award has been involved in establishing and managing the Molecular Histology Facility.
During this time the facility has established a number of strategic partnerships including Global Priority Site and Key Account with Nanostring, Key Opinion Leader with Akoya, Reference Site with Visiopharm and other collaborations including Leica Biosystems.
COVID-19 is a complex multiphase disease in which the immune system causes disease exacerbation in some patients. This talk covers how digital pathology and tissue multiplexing techniques can be combined to effectively investigate the pathophysiology of SARS-CoV-2 to better inform the optimal selection and scheduling of therapeutic approaches.
COVID-19 is a complex multiphase disease in which the immune system causes disease exacerbation in some patients. This talk covers how digital pathology and tissue multiplexing techniques can be combined to effectively investigate the pathophysiology of SARS-CoV-2 to better inform the optimal selection and scheduling of therapeutic approaches.
